Publicacions (148) Publicacions de José Luis Lanciego Pérez

2024

  1. Development and characterization of a non-human primate model of disseminated synucleinopathy

    Frontiers in Neuroanatomy, Vol. 18

2023

  1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 110

  2. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  3. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  4. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

  5. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome

    Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601

  6. Visualizing advances in the future of primate neuroscience research

    Current Research in Neurobiology, Vol. 4

2022

  1. Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives

    Biomedicines, Vol. 10, Núm. 4

  2. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment

    Life, Vol. 12, Núm. 11

  3. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

    Science Translational Medicine, Vol. 14, Núm. 627

2021

  1. Adeno-associated viral vectors as versatile tools for parkinson’s research, both for disease modeling purposes and for therapeutic uses

    International Journal of Molecular Sciences, Vol. 22, Núm. 12

  2. An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria

    Redox Biology, Vol. 46

  3. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

  4. Silencing of histone deacetylase 6 decreases cellular malignancy and contributes to primary cilium restoration, epithelial-to-mesenchymal transition reversion, and autophagy inhibition in glioblastoma cell lines

    Biology, Vol. 10, Núm. 6

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

  2. Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates

    Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164

  3. Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum

    Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42

  4. Neuroanatomical tract-tracing techniques that did go viral

    Brain Structure and Function, Vol. 225, Núm. 4, pp. 1193-1224

2019

  1. Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings

    Journal of Neurology, Vol. 266, Núm. 10, pp. 2396-2405

  2. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine

    Movement Disorders, Vol. 34, Núm. 1, pp. 9-21